Inventurus Knowledge Solutions Limited — Q2 FY26 earnings call

Call held 6 Nov 2025

Management summary

Inventurus Knowledge Solutions (IKS) delivered a strong Q2 FY26, with robust revenue growth of 22% YoY and significant margin expansion, reaching ~35% EBITDA, driven by AI-native platform adoption and successful AQuity integration. The company secured key client wins and generated strong cash flows, reducing net debt. While growth in top clients is strong, management noted continued choppiness in non-top 10 client segments due to ongoing rationalization.

Highlights

  • Revenue of INR 781 crores, up 22% YoY (5.5% QoQ), demonstrating strong growth.

  • EBITDA of INR 272 crores, up 43% YoY (14% QoQ), with EBITDA margin reaching ~35%, ahead of management's prior estimates.

  • PAT of INR 181 crores, up 60% YoY (19% QoQ), reflecting robust bottom-line performance.

  • Generated strong operating cash flow of INR 291 crores and free cash flow of INR 225 crores, with a FCF yield of 124%.

  • Successful integration of AQuity and continued progress in AI-native platform adoption driving efficiency and client value.

Concerns

  • Growth in non-top 10 clients remains 'choppy' due to ongoing client rationalization post-AQuity acquisition.

  • Management explicitly does not provide annual or quarterly guidance, citing market non-linearity, which can make future performance difficult to model.

Key financials

  1. Revenue ₹781 Cr +22%YoY
  2. EBITDA ₹272 Cr +43%YoY
  3. EBITDA Margin 35%
  4. PAT ₹181 Cr +60%YoY
  5. EPS ₹10.8
  6. ROE 32%
  7. Operating Cash Flow ₹291 Cr
  8. Free Cash Flow ₹225 Cr
  9. FCF Yield 124%
  10. Net Debt ₹412 Cr
  11. Employee Headcount 12,900
  12. Employee Benefit Expenses (% of Sales) 51%
  13. R&D Spend (% of Revenue) 5%
  14. ETR 21%

What they filed

Q1 FY27: revenue up 48.9%, net profit up 44.2% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue240 241 290 319 356 +48%404 +68%413 +42%475 +49%
EBITDA116 103 129 150 178 +53%196 +90%212 +64%219 +46%
Net profit92 83 100 113 138 +50%146 +76%169 +69%163 +44%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Order book

medium confidence

Pipeline

deal pipeline tcv

Robust interest in large platform deals, pipeline at an all-time high.

Management noted robust interest and an 'all-time high' pipeline for large platform deals, driven by the stressful environment for healthcare providers.

Source: Q&A

Capital allocation

high confidence
  • Debt Net ₹412 Cr
    • Refinance Refinanced term loan at a more attractive interest rate.
    The net debt continues to slide down in line with our strong cash generation. It stood at INR412 crores for the quarter and we hope to continue to see this number slide down in the coming quarters as well.
  • Liquidity Liquidity disclosed Generated strong operating cash flow of INR 291 crores and free cash flow of INR 225 crores, with a FCF yield of 124%.
    Cash flow was also very strong in the quarter. We had an operating cash flow of INR291 crores and a free cash flow of INR225 crores, representing a rather strong growth year-on-year and wanted to call out that FCF yield for the quarter was also rather strong at 124%.

Guidance & targets

Profitability

  • EBITDA Margin Profitability · Q2 FY26 · High confidence early to mid 30s
    Nithya and I have been saying that, as we transform the AQuity margins and as we leverage the tailwinds of Al in our business model, which by the way, were accelerated by the addition of our new Chief AI Officer, Ajai Sehgal, an ex-Microsoft leader, we will get to EBITDA margins in the early to mid 30s.

    — Sachin Gupta

Tax Rate

  • Effective Tax Rate (ETR) Tax Rate · FY26 · High confidence 21% to 21%
    ETR for the quarter stood at 21%. For the full year, the range is likely to remain in 21% to 21%, which we had earlier communicated.

    — Nithya Balasubramanian

Debt

  • Net Debt Status Debt · FY27 · High confidence net debt free
    As of now, based on the current visibility, we hope to be, I'll retain my comment earlier that we hope to be net debt free by FY '27.

    — Nithya Balasubramanian

What to watch in Q3 FY26

Net Debt Reduction

Next quarter and subsequent quarters, aiming for net debt free by FY27
Current INR 412 crores
Target Continued reduction

Why it matters

Tracking progress towards the net debt-free target by FY27 is crucial for assessing financial health and capital allocation efficiency.

The net debt continues to slide down in line with our strong cash generation. It stood at INR412 crores for the quarter and we hope to continue to see this number slide down in the coming quarters as well.

Risks & concerns

  • Client Concentration and Volatility

    medium

    High dependency on top clients (45% of revenue from top 10) and choppy growth in non-top 10 clients due to AQuity client rationalization.

    Analyst acknowledged

  • Competitive Environment

    medium

    Potential for large players like Optum to increase investments in IKS's market segment, though IKS differentiates its focus on physician groups.

    Analyst acknowledged

  • Seasonality in Patient Volumes

    low

    Revenue can be impacted by lower elective care volumes during US winter months (Dec-Feb) and summer holidays (July-Aug), though value-based care acts as a hedge.

    Both acknowledged

Q&A highlights

6 direct, 1 evasive
Guidance and Key Performance Indicators (KPIs) Evasive
We've been clear that we will not give guidance. This is an early-stage market with a very long runway ahead. And so it's not a business that has total linearity.

Management explicitly stated their policy of not providing numerical guidance, which can be a point of concern for investors seeking predictable forward-looking metrics.

Asked by Nilabja Dey

Sustainability of Margin Trajectory Direct
we're comfortable with the range of margins that we are at. And this gives us the ability to continue to make the appropriate investments in growth while being able to deliver superior bottom line benefits.

Management confirmed that current EBITDA margins (mid-30s) are sustainable despite ongoing investments in R&D and sales & marketing, providing confidence in profitability.

Asked by Chirag Kachhadiya

Client Concentration and Non-Top 10 Client Growth Partial
Ruchi, to the second part of your question on non top-10, I think it will remain choppy because we have discussed this before with you that for AQuity, we will continue to prune the number of clients. The non-top-10 growth is likely to remain choppy going forward.

Revealed a deliberate strategy of client rationalization post-AQuity acquisition, leading to choppy growth in smaller client segments, which is a short-term trade-off for higher quality, long-term relationships.

Asked by Ruchi Mukhija

Impact of AI and Platform on Value Creation and Margins Direct
So our estimate is that if the full manifest of our platform and customers buy it one by one, each of the tasks one by one, if the value is say 700 basis points in EBITDA expansion for them. If they buy the full platform at once and we implement it as one platform where the features compound in value, that 700 basis points can go up to as much as 900 basis points because of the compounding effect.

Provided a detailed explanation of how IKS's AI-native platform creates compounding value for clients (up to 900 bps EBITDA expansion) and for the company through revenue share and Net Economic Value Add (NEVA).

Asked by Chetan Shah

Competitive Landscape and Optum's Strategy Direct
The products that you highlight are predominantly geared towards the hospital market, which is their core market... Optum Health actually is one of our major clients, right? And so they leverage revenue cycle services for the physician market.

Addressed competitive concerns by clarifying IKS's focus on the physician market versus Optum's primary strength in hospital RCM, while acknowledging potential competition from Optum Health.

Asked by Omkar Sawant

Customer Focus for Achieving $1 Billion Revenue Direct
we have actually zoned in on about 50 customers that each have a potential of $50 million each ACV in the next, say, five years... if we converted, say, between 10 to 15 of those 50 over the next five years, that is somewhere between $0.5 billion to $750 million of additional growth.

Outlined the company's growth strategy, focusing on deep penetration within a select cohort of ~50 large, high-potential clients to drive significant future revenue growth.

Asked by Sandeep Kothari

Significance of Google Cloud and Epic Integration Direct
Epic is the underlying core platform in maybe 75%, 80% of the large health systems in the country. And integrating our platform with Epic is a very, very critical component of our strategy.

Highlighted the critical strategic importance of integrating IKS's platform with Epic EHR, which is dominant in large health systems, to enhance competitive positioning and market access.

Asked by Sandeep Kothari

Employee Headcount Increase and Organic Growth Direct
The absolute headcount growth between last quarter and this quarter, yes, there is actually some significant customer ramps that have happened where there is you within the loop required and that is the absolute headcount growth, that actually is welcome headcount growth to be perfectly honest, because that actually signals tremendous organic growth in revenue.

Explained the recent increase in headcount as a direct response to significant customer ramps and organic growth, reinforcing the non-linearity of the business model where headcount growth is lower than revenue growth YoY.

Asked by Ruchi Mukhija

2 min read 6 chapters

Detailed narrative

Strong Q2 FY26 Financial Performance

Inventurus Knowledge Solutions reported robust financial results for Q2 FY26, with revenue growing 22% year-on-year and 5.5% quarter-on-quarter to INR 781 crores. This growth translated into significant profitability, with EBITDA expanding 43% YoY and 14% QoQ to INR 272 crores, achieving an EBITDA margin of approximately 35%. Net profit also saw substantial growth, increasing 60% YoY and 19% QoQ to INR 181 crores, resulting in an EPS of INR 10.8 and a healthy ROE of 32%.

AI-Native Platform and Strategic Pillars

The company emphasized its transition to an AI-native and agentic platform, integrating autonomous clinical documentation with financial workflows. This platform is designed to solve cost, quality, and access challenges in the $5 trillion U.S. healthcare system. Management highlighted continued progress in leveraging AI for denial prevention, patient financial clearance, optimized scheduling, and physician productivity, transforming unstructured data into structured, meaningful insights.

AQuity Integration and Margin Expansion

The successful integration of the AQuity acquisition, now almost two years in, has been a key driver of margin expansion. The company transformed AQuity's delivery model through technology and global human execution, achieving its target EBITDA margins in the mid-30s several quarters ahead of schedule. This efficiency gain, coupled with the AI-driven elimination of human intervention, significantly contributed to the improved bottom line performance.

Client Strategy and Growth Drivers

IKS's strategy focuses on deep penetration within a cohort of approximately 50 enterprise-scale customers, each with a potential of $50 million ACV over the next five years, which could generate $0.5 billion to $750 million in additional growth. The company secured new client wins and expansions, including AdventHealth, Revere Health, The Jackson Clinic, and a leading cardiology group, demonstrating strong platform adoption. While top clients show robust growth, management noted that growth in non-top 10 clients remains 'choppy' due to ongoing client rationalization post-AQuity acquisition, aiming for long-term relationships with the top 500 clients.

Capital Allocation and Debt Management

The company maintains a capital-light business model, generating strong cash flows, with operating cash flow at INR 291 crores and free cash flow at INR 225 crores, yielding a 124% FCF. Net debt reduced to INR 412 crores this quarter, and management aims to be net debt-free by FY27, supported by strong cash generation and a refinanced term loan at a more attractive interest rate. Capital allocation priorities include strategic tuck-in technology acquisitions and aligning with customer outcomes through long-term platform deals.

Market Opportunity and Competitive Landscape

The U.S. healthcare market, particularly the physician segment, represents a $260 billion TAM growing at 8%, with the outsourced TAM growing at 12%. IKS aims to gain market share by growing faster than 12%. Management addressed competitive concerns regarding large players like Optum, clarifying that IKS primarily targets the physician market, while Optum's core RCM strength is hospital-focused. Strategic integrations, such as with Epic Electronic Health Record software, are deemed critical for IKS's competitive advantage in serving large health systems.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Information Technology earnings calls